Carregant...
Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4177103/ https://ncbi.nlm.nih.gov/pubmed/25182864 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-014-0149-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|